Yi-Wen Zhu, Zi-Tao Liu, Ao-Qi Tang, Xiao-Yi Liang, Yan Wang, Ya-Fang Liu, Yu-Qing Jin, Wei Gao, Hang Yuan, Da-Yong Wang, Xin-Ying Ji, Dong-Dong Wu
{"title":"硫化氢在铁变态反应中的新作用。","authors":"Yi-Wen Zhu, Zi-Tao Liu, Ao-Qi Tang, Xiao-Yi Liang, Yan Wang, Ya-Fang Liu, Yu-Qing Jin, Wei Gao, Hang Yuan, Da-Yong Wang, Xin-Ying Ji, Dong-Dong Wu","doi":"10.1089/ars.2023.0535","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Significance:</i></b> Ferroptosis, a form of regulated cell death characterized by a large amount of lipid peroxidation-mediated membrane damage, joins the evolution of multisystem diseases, for instance, neurodegenerative diseases, chronic obstructive pulmonary disease, acute respiratory distress syndrome, osteoporosis, osteoarthritis, and so forth. Since being identified as the third gasotransmitter in living organisms, the intricate role of hydrogen sulfide (H<sub>2</sub>S) in ferroptosis has emerged at the forefront of research. <b><i>Recent Advances:</i></b> Novel targets in the relevant metabolic pathways have been found, including transferrin receptor 1, cystine/glutamate antiporter, and others, coupled with the exploration of new signaling pathways, particularly the p53 signaling pathway, the nitric oxide/nuclear factor erythroid 2-related factor 2 signaling pathway, and so on. Many diseases such as emphysema and airway inflammation, myocardial diseases, endothelial dysfunction in aging arteries, and traumatic brain injury have recently been found to be alleviated directly by H<sub>2</sub>S inhibition of ferroptosis. Safe, effective, and tolerable novel H<sub>2</sub>S donors have been developed and have shown promising results in phase I clinical trials. <b><i>Critical Issues:</i></b> Complicated cross talk between the ferroptosis signaling pathway and oncogenic factors results in the risk of cancer when inhibiting ferroptosis. Notably, targeted delivery of H<sub>2</sub>S is still a challenging task. <b><i>Future Directions:</i></b> Discovering more reliable and stable novel H<sub>2</sub>S donors and achieving their targeted delivery will enable further clinical trials for diseases associated with ferroptosis inhibition by H<sub>2</sub>S, determining their safety, efficacy, and tolerance.</p>","PeriodicalId":8011,"journal":{"name":"Antioxidants & redox signaling","volume":" ","pages":""},"PeriodicalIF":5.9000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Emerging Roles of Hydrogen Sulfide in Ferroptosis.\",\"authors\":\"Yi-Wen Zhu, Zi-Tao Liu, Ao-Qi Tang, Xiao-Yi Liang, Yan Wang, Ya-Fang Liu, Yu-Qing Jin, Wei Gao, Hang Yuan, Da-Yong Wang, Xin-Ying Ji, Dong-Dong Wu\",\"doi\":\"10.1089/ars.2023.0535\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Significance:</i></b> Ferroptosis, a form of regulated cell death characterized by a large amount of lipid peroxidation-mediated membrane damage, joins the evolution of multisystem diseases, for instance, neurodegenerative diseases, chronic obstructive pulmonary disease, acute respiratory distress syndrome, osteoporosis, osteoarthritis, and so forth. Since being identified as the third gasotransmitter in living organisms, the intricate role of hydrogen sulfide (H<sub>2</sub>S) in ferroptosis has emerged at the forefront of research. <b><i>Recent Advances:</i></b> Novel targets in the relevant metabolic pathways have been found, including transferrin receptor 1, cystine/glutamate antiporter, and others, coupled with the exploration of new signaling pathways, particularly the p53 signaling pathway, the nitric oxide/nuclear factor erythroid 2-related factor 2 signaling pathway, and so on. Many diseases such as emphysema and airway inflammation, myocardial diseases, endothelial dysfunction in aging arteries, and traumatic brain injury have recently been found to be alleviated directly by H<sub>2</sub>S inhibition of ferroptosis. Safe, effective, and tolerable novel H<sub>2</sub>S donors have been developed and have shown promising results in phase I clinical trials. <b><i>Critical Issues:</i></b> Complicated cross talk between the ferroptosis signaling pathway and oncogenic factors results in the risk of cancer when inhibiting ferroptosis. Notably, targeted delivery of H<sub>2</sub>S is still a challenging task. <b><i>Future Directions:</i></b> Discovering more reliable and stable novel H<sub>2</sub>S donors and achieving their targeted delivery will enable further clinical trials for diseases associated with ferroptosis inhibition by H<sub>2</sub>S, determining their safety, efficacy, and tolerance.</p>\",\"PeriodicalId\":8011,\"journal\":{\"name\":\"Antioxidants & redox signaling\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2024-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antioxidants & redox signaling\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1089/ars.2023.0535\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antioxidants & redox signaling","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/ars.2023.0535","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
The Emerging Roles of Hydrogen Sulfide in Ferroptosis.
Significance: Ferroptosis, a form of regulated cell death characterized by a large amount of lipid peroxidation-mediated membrane damage, joins the evolution of multisystem diseases, for instance, neurodegenerative diseases, chronic obstructive pulmonary disease, acute respiratory distress syndrome, osteoporosis, osteoarthritis, and so forth. Since being identified as the third gasotransmitter in living organisms, the intricate role of hydrogen sulfide (H2S) in ferroptosis has emerged at the forefront of research. Recent Advances: Novel targets in the relevant metabolic pathways have been found, including transferrin receptor 1, cystine/glutamate antiporter, and others, coupled with the exploration of new signaling pathways, particularly the p53 signaling pathway, the nitric oxide/nuclear factor erythroid 2-related factor 2 signaling pathway, and so on. Many diseases such as emphysema and airway inflammation, myocardial diseases, endothelial dysfunction in aging arteries, and traumatic brain injury have recently been found to be alleviated directly by H2S inhibition of ferroptosis. Safe, effective, and tolerable novel H2S donors have been developed and have shown promising results in phase I clinical trials. Critical Issues: Complicated cross talk between the ferroptosis signaling pathway and oncogenic factors results in the risk of cancer when inhibiting ferroptosis. Notably, targeted delivery of H2S is still a challenging task. Future Directions: Discovering more reliable and stable novel H2S donors and achieving their targeted delivery will enable further clinical trials for diseases associated with ferroptosis inhibition by H2S, determining their safety, efficacy, and tolerance.
期刊介绍:
Antioxidants & Redox Signaling (ARS) is the leading peer-reviewed journal dedicated to understanding the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease. The Journal explores key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics. Cutting-edge research focuses on structural biology, stem cells, regenerative medicine, epigenetics, imaging, clinical outcomes, and preventive and therapeutic nutrition, among other areas.
ARS has expanded to create two unique foci within one journal: ARS Discoveries and ARS Therapeutics. ARS Discoveries (24 issues) publishes the highest-caliber breakthroughs in basic and applied research. ARS Therapeutics (12 issues) is the first publication of its kind that will help enhance the entire field of redox biology by showcasing the potential of redox sciences to change health outcomes.
ARS coverage includes:
-ROS/RNS as messengers
-Gaseous signal transducers
-Hypoxia and tissue oxygenation
-microRNA
-Prokaryotic systems
-Lessons from plant biology